Abstract
Early immunotherapy can improve progression-free survival (PFS) without affecting overall survival (OS) for patients with locally advanced or metastatic esophageal squamous cell cancer (ESCC).
Introduction
In the rapidly evolving landscape of oncology, immunotherapy has transitioned from a "last-resort" treatment to a cornerstone of care. For patients with advanced esophageal squamous cell cancer (ESCC), the clinical question is no longer whether they should receive immunotherapy, but rather when it should be initiated. A recent retrospective study published in Frontiers in Medicine addresses this "earlier or later" debate, comparing first-line (early) versus second-line (late) immunotherapy.
Esophageal cancer is notoriously aggressive, particularly in China, where it presents high morbidity and mortality rates. While phase III clinical trials have confirmed that immune checkpoint inhibitors (ICIs), such as PD-1 inhibitors, improve survival in both first-line and second-line settings, real-world data comparing the strategic timing of these interventions remains scarce. Clinicians face a dilemma: utilize ICIs immediately to maximize initial response or reserve them as a powerful second-line option after traditional chemotherapy failure.
Methods
Researchers conducted a retrospective analysis of 359 patients with unresectable locally advanced or metastatic ESCC treated at Shandong Cancer Hospital between 2018 and 2021. Inclusion criteria required pathologically confirmed ESCC and an ECOG performance status of 0–1. Patients in the "Early Immunotherapy" (EIT) group received PD-1 inhibitors (e.g., camrelizumab or sintilimab) combined with chemotherapy as first-line treatment. The "Late Immunotherapy" (LIT) group received ICIs in the second-line setting.
To ensure a rigorous comparison and mimic randomization, the study employed Propensity Score Matching (PSM). This statistical technique balanced the groups based on observable covariates, including age, sex, tumor location, and metastatic sites. After matching, the analysis focused on 107 patients in each cohort. The primary endpoint was Overall Survival (OS), with secondary endpoints including Progression-Free Survival (PFS1 and PFS2).
Results
Progression-Free Survival
The study found that starting immunotherapy in the first-line setting significantly improves progression-free survival. The median PFS1 was 8.7 months for the EIT group compared to 7.6 months for the LIT group (p = 0.032). This suggests that early intervention is more effective at delaying initial disease progression.
Overall Survival
Despite the advantage in PFS, the EIT group did not demonstrate a statistically significant improvement in overall survival compared to the LIT group. The median OS was 15.7 months for EIT versus 17.7 months for LIT (p = 0.185). Multivariate analysis identified the timing of immunotherapy and the degree of tumor differentiation as independent factors impacting OS.
Discussion
The OS Paradox
The finding that improved PFS did not translate to improved OS—the "OS Paradox"—is a critical insight. The authors attribute this to a "cross-over" effect: patients in the LIT group eventually received immunotherapy, which likely mitigated the initial survival disadvantage. Furthermore, a higher percentage of LIT patients (30%) were able to transition to third-line therapies compared to the EIT group (15.5%), potentially extending their overall survival.
Subgroup Sensitivity and Synergy
Subgroup analysis revealed that the benefits of early immunotherapy are not uniform. Male patients, those under 65, and individuals with middle thoracic tumors or limited (single-site) metastasis showed a stronger positive response to early intervention. Additionally, the study suggests that the TP regimen (paclitaxel + platinum) may be a more effective partner for early immunotherapy than other combinations in this population.
Limitations and Future Directions
As a single-center retrospective study, these findings are subject to inherent selection and loss-to-follow-up biases. A significant limitation was the lack of PD-L1 expression data for most patients, which is a key predictor of ICI efficacy. Future research should focus on prospective, multi-center trials that integrate molecular biomarkers to personalize the timing of immunotherapy.
Conclusion
For patients with advanced ESCC, the "earlier" approach is superior for extending the time before the first disease progression, particularly in specific high-benefit subgroups. However, the overall survival benefit remains comparable to sequential treatment, highlighting the need for individualized treatment strategies.
Summary updated